BXP Beximco Pharmaceuticals PLC.
Beximco Pharmaceuticals PLC. manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh and internationally. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. Beximco Pharmaceuticals PLC. was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Beximco Pharmaceuticals PLC. (LON: BXP)
›
Beximco Pharmaceuticals PLC. (LON: BXP) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 6,000 employees.
The shares were at 57.50 GBp on 19 November 2026, up 37.0% over 52 weeks. Its 52-week range is 36.70 GBp to 65.00 GBp: the price is 11.5% below the high and 56.7% above the low.
At a market capitalisation of 256.51M GBP, it trades at 4.8 times trailing earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 81% for BXP. It pays a dividend yielding 6.36%, against a median of 1.90% among the dividend payers in that peer group.
Beximco Pharmaceuticals PLC. reports return on equity of 13.1%, an operating margin of 0.0% and revenue up 6.3% year over year.
Its Piotroski F-score is 9 out of 9, a strong reading of its financial health.